Moreover, only mice that received anti-CD3 ab, anti-CD8 ab, and MPS (p = 0.05) developed adenocarcinomas after 4 weeks of therapy, while all the other groups only developed adenomas (Fig. 3d). Here, CD8A is linked to adenocarcinoma.